SCHEMBL7521458

SCHEMBL7521458

CCNc1cc2ncnc(NCc3ccc(N4CCCC(CO)C4)cc3)c2cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.43
MAPT P10636 5/20 0.42
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
EGFR P00533 2/20 0.38
CYP3A4 P08684 1/20 0.38
CCR4 P51679 1/20 0.38
DCTPP1 Q9H773 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
PRKDC P78527 1/20 0.36
HTR6 P50406 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7522631 0.88 MAPT (0.55) PDGFRBMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL7518944 0.87 MAPT (0.54) PDGFRBMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL7521436 0.86 PDE5A (0.48) PDGFRBMAPTALDH1A1EGFRMAPK1
SCHEMBL7528397 0.83 MAPK1 (0.57) PDGFRBMAPTALDH1A1NPSR1EGFR
SCHEMBL7523791 0.83 MAPT (0.53) PDGFRBMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL7526582 0.82 PDGFRB (0.46) PDGFRBMAPTALDH1A1EGFRDCTPP1
SCHEMBL7519928 0.82 MAPT (0.45) PDGFRBMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL8795709 0.81 EGFR (0.49) PDGFRBALDH1A1EGFRMAPK1HTT
SCHEMBL8796240 0.79 EGFR (0.45) PDGFRBMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL8796234 0.79 PIK3CA (0.45) PDGFRBMAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-12-19 US disclosed
US-6127541-A 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-10-03 US disclosed
EP-0863144-A1 IMIDAZOQUINAZOLINE DERIVATIVES Kyowa Hakko Co., Ltd. (JP) 1998-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives MKI67, HRAS, VHL PDGFRB 3113/4885MAPT 4593/4885CYP1A2 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.